NDLTD logo NDLTD Union Catalog and Global ETD Search

Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 365 for “"ovarian cancer"”.

  1. Arsenic trioxide in ovarian cancer

    ONG PEI SHI2008

    … responsible for its cytotoxicity against ovarian carcinoma remain elusive. In this thesis, the molecular determinants of its effects and factors mediating its chemoresistance in ovarian cancer cells were investigated. It was found that As2O3 treatment caused both apoptosis induction and …

    nus Repository record

  2. BMP9 Signalling in Ovarian Cancer

    Walsh, PeterUniversity of Dundee2015

    Ovarian Cancer is the 5th most common cause of cancer death in women and the second most common gynaecological cancer in the UK. Worldwide, around 152,000 women were estimated to have died from ovarian cancer in 2012. Survival rates for women with epithelial ovarian cancer have not significantly …

    dundee Repository record

  3. The mechanism of ovarian cancer chemoresistance

    Deng, JunliUNSW, Sydney2018

    Ovarian cancer (OC) is the leading cause of female reproductive tract cancer mortality in the world. Although cytoreductive surgery followed by platinum/taxane acts a standard therapy and contributes to a high initial response rate, most patients will ultimately develop tumour recurrence and …

    unsw Repository record

  4. Estrogen in ovarian cancer cell metastasis

    Park, Se HyungUniversity of British Columbia2008

    Benign ovarian tumors and majority of epithelial ovarian cancers possess steroid receptors including estrogen receptors (ERs). However, the estrogen-ER signaling in ovarian carcinomas is not completely understood. Tumorigenesis is a multiple-step process involving dysregulated cell growth and …

    ubc Repository record

  5. The Role of Gdf15 In Ovarian Cancer

    Izaguirre, Daisy I2021

    … as a potential biomarker in several types of cancer as well as in other diseases such as cardiovascular diseases, diabetes, and rheumatoid arthritis. In ovarian cancer, high GDF15 serum levels correspond to poor survival. It has further been shown to be expressed at higher levels in serum in …

    uthsc Repository record

  6. Ovarian cancer serum biomarker discovery using proteomics

    Kabir, M.UCL (University College London)2009

    Ovarian cancer is a lethal gynaecological malignancy which is known as the silent killer. It has a poor prognosis due to the lack of major symptoms in early stage disease and hence its late detection. Cancer antigen-125, the most widely used biomarker for ovarian cancer detection, lacks appropriate …

    ucl Repository record

  7. Modeling Epithelial Ovarian Cancer In The Mouse

    Flesken-Nikitin, AndreaCornell University2011

    For over five decades epithelial ovarian cancer (EOC) is identified as the leading cause of death from gynecological malignancies in the USA. Unfortunately, due to latent progression of EOC and lack of accurate animal models studies of this disease's pathogenesis have been challenging. Not …

    cornell Repository record

  8. ING1 Impacts Ovarian Cancer by Altering EMT

    Yang, YangCumming School of Medicine2019

    … transition (EMT) program that suppresses cancer metastasis and identifies the mechanism of how ING1 regulates gene transcription, as well as its clinical implication in epithelial ovarian cancer. Our analyses revealed that ING1 epigenetically regulates the transcription machinery of the …

    calgary Repository record

  9. Inflammatory Factor and Biomarkers for Epithelial Ovarian Cancer

    Alsulimani, AhmadState University of New York at Buffalo2022

    Ph.D.

    buffalo Repository record

  10. Commonly used medications and survival from ovarian cancer

    Harding, Barbara N2019

    Background: Ovarian cancer is the 5th leading cause of cancer-related death among women in the United States. Typically diagnosed as a late stage disease, it follows an aggressive clinical course resulting in 5-year survival proportions of less than 50% for all stages and less than 30% for advanced …

    washington Repository record

  11. Downregulation of Pax2 Suppresses Ovarian Cancer Cell Growth

    song, huijuan2012

    … <em>PAX2</em> has been found in several cancer types. We therefore sought to elucidate the role of PAX2 in ovarian carcinomas. We found that PAX2 was expressed in low-grade serous, clear cell, endometrioid and mucinous cell ovarian carcinomas, which are relatively chemoresistant compared …

    uthsc Repository record

  12. Molecular Determinants of Residual Disease In Ovarian Cancer

    Gharpure, Kshipra M, <p>0000-0003-4954-5696</p>2018

    <p>The standard treatment for high grade serous ovarian cancer is primary cytoreductive surgery followed by adjuvant chemotherapy. Residual disease followed by surgery is associated with adverse overall and progression-free survival as well as poor response to adjuvant chemotherapy. Accurate …

    uthsc Repository record

  13. Managing Susceptibility to Hereditary Breast and Ovarian Cancer

    Perry, Cynthia E., PhD, MSN, RN2021

    The recent identification of Breast Cancer 1 (BRCA1) and BRCA2 genes offers an opportunity for high-risk individuals to learn whether they may be genetically predisposed to develop breast and/or ovarian cancer. The purpose of this study was to examine how unaffected women, identified as BRCA …

    usd-thes Repository record

  14. Clinical resistance to platinum chemotherapy in ovarian cancer

    Newton, C.UCL (University College London)2009

    Platinum drugs are the most active agents in ovarian cancer. Their cytotoxicty results from DNA crosslinking. High tumour response rates are seen, but 80 % of patients relapse. Major mechanisms of platinum resistance in patients remain to be established. We have studied DNA interstrand crosslinking …

    ucl Repository record

  15. NANOPARTICLE DEPOT FOR INTRAPERITONEAL CHEMOTHERAPY OF OVARIAN CANCER

    Sun, Bo

    … is a promising post-surgical therapy of ovarian cancer, with the full potential yet to be proven. To facilitate IP chemotherapy of ovarian cancer, we have developed a nanoparticle depot for IP chemotherapy consisted of paclitaxel (PTX) nanocrystals (PNC) and hyaluronic acid-based hydrogel …

    purdue-thes Repository record

  16. Hormones and growth factors in ovarian cancer cells

    Crew, Amanda JayneThe University of Edinburgh1992

    edinburgh Repository record

  17. Characterisation of the Tumour Microenvironment in Ovarian Cancer

    Jiménez Sánchez, AlejandroUniversity of Cambridge2019

    The tumour microenvironment comprises the non-cancerous cells present in the tumour mass (fibroblasts, endothelial, and immune cells), as well as signalling molecules and extracellular matrix. Tumour growth, invasion, metastasis, and response to therapy are influenced by the tumour …

    cambridge Repository record

  18. Roles of PKR in High Grade Serous Ovarian Cancer

    Afzali, Farzaneh2026

    High-grade serous ovarian carcinoma (HGSC) is characterized by dissemination within the peritoneal cavity, a process that critically depends on dynamic regulation of cell adhesion, migration, and invasion rather than primary tumor growth. Protein kinase R (PKR; EIF2AK2) is classically described as …

    queens Repository record

  19. Identification of Novel Prognostic Biomarkers in Epithelial Ovarian Cancer

    Stenzel, AshleyState University of New York at Buffalo2025

    Ph.D.

    buffalo Repository record

  20. Mapping the Landscape of Acquired Vulnerabilities in Ovarian Cancer

    Shields, Benjamin Baker2015

    … to identify the genetic lesions associated with ovarian cancer have noted the striking diversity of mutations occurring in this disease. This genetic diversity has complicated the search for novel therapies. However, recent data has suggested that one commonality of ovarian tumors might be …

    utswmed Repository record

Page 1 of 19